Ideaya Biosciences Inc

NASDAQ:IDYA  
16.84
+0.50 (+3.06%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)504.81M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$9.07 Million
Adjusted EPS-$0.33
See more estimates
10-Day MA$15.47
50-Day MA$14.08
200-Day MA$11.57
See more pivots

IDEAYA Biosciences, Inc. Stock, NASDAQ:IDYA

7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO, CA 94080
United States of America
Phone: 650-443-6209
Number of Employees:

Description

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.